Clinical Trials Logo
  1. Home
  2. Mucormycosis
  3. NCT03387696

Mucormycosis in ICU — ZygoRéa  

Mucormycosis Clinical Trial

Official title:
Mucormycosis in ICU: A French Multicenter Cohort Study

Clinical Trial Summary

Mucormycosis is an invasive fungal infection affecting patients with various clinical conditions especially patients with heavy immunosuppression or patients with trauma or extensive burns. ZygoRéa is a retrospective and multicentric French study aimed to evaluate survival of patients with mucormycosis admitted in ICU at day-28 after admission. This study will also try also to describe the epidemiology of patients admitted in ICU.

Clinical Trial Description

Mucormycosis is an invasive fungal infection affecting patients with various clinical conditions especially patients with heavy immunosuppression or patients with trauma or extensive burns. The incidence of Mucormycosis is currently increasing reaching 7% of invasive fungal infections in some immunocompromised patients. Because of its aggressive nature, Mucormycosis is associated with poor survival and high morbidity ; mortality is estimated between 16% and 64% according to different retrospective studies. No study has ever evaluated prognosis of patients with mucormycosis admitted in intensive care units (ICU). ZygoRéa is a retrospective and multicentric French study aimed to evaluate survival of patients with mucormycosis admitted in ICU at day-28 after admission. This study will also try also to describe the epidemiology of patients admitted in ICU and to evaluate the prognosis of different subgroups of patients according to : - their clinical characteristics : demographic characteristics, clinical conditions and factors of immunosuppression - the characteristics of the fungal infection - the treatment strategy - the severity of the initial illness, evaluated by severity scores Twenty-one French ICU are currently including more than 45 patients. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT03387696
Study type Observational
Source University Hospital, Grenoble
Contact
Status Completed
Phase
Start date September 8, 2017
Completion date June 1, 2018
View Details
See also
  Status Clinical Trial Phase
Recruiting NCT04744454 - Post Marketing Surveillance (PMS) Study of Cresemba in Korea.
Completed NCT00419770 - The Deferasirox-AmBisome Therapy for Mucormycosis (DEFEAT Mucor) Study Phase 2
Recruiting NCT05925660 - Mucorales PCR Screening in At-risk Hematology Patients N/A
Completed NCT04935463 - Mucormycosis in COVID-19
Completed NCT04550936 - Patterns of Real-World Isavuconazole Use - a Study of Patients With Mucormycosis or Invasive Aspergillosis
Completed NCT05074043 - COVID-19 Associated Mucormycosis: A Multidisciplinary Dilemma in Assiut University Hospital
Not yet recruiting NCT05406037 - Biomarkers for Invasive Mucormycosis
Not yet recruiting NCT06440915 - Study on Theraputic Drug Monitoring and Phamacokinetics of Isavuconazole in Children N/A
Completed NCT02845934 - Prospective Evaluation of a New Molecular Tool for Early Diagnosis of Mucormycosis N/A
Completed NCT05348434 - Evaluation of Using 3D Printed PEEK Facial Implants in Repairing Maxillofacial Deformities
Completed NCT05212961 - COVID-19 and Rhino-orbital Mucormycosis
Recruiting NCT05097664 - Ocular Manifestation and Related Risk Factors of Covid-19 Associated Mucormycosis: a Multicenter Study in Iran